Cover Image
市場調查報告書

醫藥品分析:登革熱疫苗

Disease Overview: Dengue Vaccines

出版商 Datamonitor Healthcare 商品編碼 365203
出版日期 內容資訊 英文 83 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品分析:登革熱疫苗 Disease Overview: Dengue Vaccines
出版日期: 2018年01月04日 內容資訊: 英文 83 Pages
簡介

本報告提供登革熱疫苗市場相關調查分析,上市疫苗,開發平台疫苗焦點,現況與展望等系統性資訊。

上市疫苗:登革熱

  • 摘要整理
  • 產品簡介:DENGVAXIA

開發平台疫苗:登革熱

  • 摘要整理
  • 臨床開發平台概要
  • 一次調查手法
  • 產品簡介 (後期) :DPIV
  • 產品簡介 (後期) :DENGUE DNA VACCINE
  • 產品簡介 (後期) :TAK-003
  • 產品簡介 (後期) :TETRAVAX-DV
  • 產品簡介 (後期) :V180

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC12929

Disease Overview

Dengue fever is an emerging flaviviral infection transmitted mainly by Aedes aegypti and Aedes albopictus mosquitoes. The dengue burden has expanded rapidly over the last few decades, and the disease is now endemic in many Latin American and Asia-Pacific countries, with 75% of the at-risk population residing in the latter region. Dengue usually manifests as a severe flu-like illness, with symptoms including headache, retro-orbital pain, muscle pain, and vomiting, but 1-3% of infections will manifest as dengue hemorrhagic fever, characterized by plasma leakage, severe bleeding, and respiratory distress.

Market Snapshot

Safety concerns in seronegative patients will severely lower Dengvaxia's uptake for the foreseeable future.

TAK-003 is expected to replace Dengvaxia as the preferred vaccine for routine immunizations in lucrative Asia-Pacific markets.

CONTENTS

5 MARKETED VACCINES: DENGUE FEVER (Published on 04 January 2018)

5 EXECUTIVE SUMMARY

6 PRODUCT PROFILE: DENGVAXIA

29 PIPELINE VACCINES: DENGUE FEVER (Published on 04 January 2018)

29 EXECUTIVE SUMMARY

30 CLINICAL PIPELINE OVERVIEW

32 PRIMARY RESEARCH METHODOLOGY

33 PRODUCT PROFILE (LATE STAGE): DPIV

42 PRODUCT PROFILE (LATE STAGE): DENGUE DNA VACCINE

48 PRODUCT PROFILE (LATE STAGE): TAK-003

62 PRODUCT PROFILE (LATE STAGE): TETRAVAX-DV

74 PRODUCT PROFILE (LATE STAGE): V180

LIST OF FIGURES

  • 8 Figure 1: Dengvaxia vaccine design
  • 21 Figure 2: Dengvaxia for dengue fever - SWOT analysis
  • 39 Figure 3: DPIV for dengue fever - SWOT analysis
  • 46 Figure 4: Dengue DNA Vaccine for dengue fever - SWOT analysis
  • 50 Figure 5: Design of the TAK-003 vaccine
  • 57 Figure 6: TAK-003 for dengue fever - SWOT analysis
  • 64 Figure 7: Design of the TetraVax-DV vaccine
  • 70 Figure 8: TetraVax-DV for dengue fever - SWOT analysis
  • 80 Figure 9: V180 for dengue fever - SWOT analysis

LIST OF TABLES

  • 7 Table 1: Dengvaxia drug profile
  • 9 Table 2: Dengvaxia pivotal trial data in dengue fever
  • 19 Table 3: Dengvaxia ongoing late-phase trials in dengue fever
  • 31 Table 4: Pipeline products in development for dengue fever prophylaxis
  • 34 Table 5: DPIV drug profile
  • 36 Table 6: DPIV completed Phase I studies in dengue fever
  • 39 Table 7: DPIV ongoing studies in dengue fever
  • 43 Table 8: Dengue DNA Vaccine drug profile
  • 44 Table 9: Dengue DNA Vaccine Phase I data in dengue fever
  • 46 Table 10: Dengue DNA Vaccine Phase I data in dengue fever
  • 47 Table 11: Potential dosing schedules of early-phase dengue fever vaccine candidates
  • 49 Table 12: TAK-003 drug profile
  • 51 Table 13: TAK-003 completed studies in dengue fever
  • 55 Table 14: TAK-003 ongoing studies in dengue fever
  • 56 Table 15: TAK-003 Phase II trial data in dengue fever
  • 63 Table 16: TetraVax-DV drug profile
  • 65 Table 17: TetraVax-DV completed studies in dengue fever
  • 67 Table 18: TetraVax-DV ongoing studies in dengue fever
  • 75 Table 19: V180 drug profile
  • 76 Table 20: V180 Phase I data in dengue fever

 

Back to Top